IRON is tracked by BiotechSign with a current catalyst score of 31/100 and grade F. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, Disc Medicine (IRON) has a BiotechSign Catalyst Score of 31/100, rated F. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
Disc Medicine (IRON) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 4 Phase 2[2], 3 Phase 1[3].
Trial NCT05883748[5] evaluates DISC-1459 in Erythropoietic Protoporphyria with a target enrollment of 230 participants. Trial NCT06910358[6] evaluates Placebo in Erythropoietic Protoporphyria (EPP) with a target enrollment of 150 participants.
No Form 4 insider filings for IRON were recorded at the SEC in the past 30 days[7].